A prospective study of adverse reactions associated with vancomycin therapy.
about
Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in ratsVancomycin enhancement of experimental tobramycin nephrotoxicityVancomycin- and erythromycin-induced hearing loss in humansVancomycin-associated nephrotoxicity: grave concern or death by character assassination?Mycobacterium avium-M. intracellulare and Acquired Immunodeficiency Syndrome.Outcome assessment of minimizing vancomycin monitoring and dosing adjustments.Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort studyEffective treatment of cephalosporin-rifampin combinations against cryptic methicillin-resistant beta-lactamase-producing coagulase-negative staphylococcal experimental endocarditisIntrarenal distribution of vancomycin in endotoxemic ratsCurrent perspectives on glycopeptide resistance.Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections.Alanine aminopeptidase and beta 2-microglobulin excretion in patients receiving vancomycin and gentamicin.Methicillin-resistant staphylococci: detection methods and treatment of infections.Extensive thrombophlebitis with gas associated with continuous infusion of vancomycin through a central venous catheterThe pharmacokinetic and pharmacodynamic properties of vancomycin.Large Cohort Study of Central Venous Catheter Thrombosis during Intravenous Antibiotic Therapy.Implementation of an antibiotic nomogram improves postoperative antibiotic utilization and safety in patients undergoing coronary artery bypass grafting.Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicityMethicillin-resistant staphylococci.Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.Subcellular localization of tobramycin and vancomycin given alone and in combination in proximal tubular cells, determined by immunogold labeling.Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections.Vancomycin utilization evaluation at hematology-oncology ward of a teaching hospital in iran.Third generation cephalosporins: safety profiles after 10 years of clinical use.Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.Vancomycin therapeutics and monitoring: a contemporary approach.The Nephrotoxicity of VancomycinVancomycin Prophylaxis for Total Joint Arthroplasty: Incorrectly Dosed and Has a Higher Rate of Periprosthetic Infection Than Cefazolin.Cost perspectives for outpatient intravenous antimicrobial therapy.Predictive performance of a vancomycin-aminoglycoside population model.Pediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring.Adverse effects of vancomycin in children: a review of 22 cases.Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice.Polyethylene glycol nephrotoxicity secondary to prolonged high-dose intravenous lorazepam.The effect of tobramycin on the renal handling of vancomycin.Establishment of norvancomycin fluorescence polarization immunoassay for therapeutic drug monitoring.Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy
P2860
Q28330353-6ECA263A-5969-443E-A107-DE0124B424D1Q28362084-93777972-5B0C-4F71-A7E7-33053262264AQ30502734-AEB93328-3038-408B-8F12-948F2F2586B2Q33617737-3944DCEC-48E6-48F2-A91F-10E9ECFB95B5Q33741753-6013B0AE-B32E-44FB-9B4B-4538F80DAF26Q33860155-02DD3AB0-5A4D-40FC-A585-795CF7B646C3Q34583169-A44A9405-39B4-4CF2-80F4-ADF8A85A2EABQ35117426-8586182A-699B-4ED9-B167-66F491BA1474Q35350008-A769AC61-4958-4748-986B-A4E5ECB83ADFQ35368590-3928E581-4B26-4374-8271-8F64F913F424Q35536476-34D104DB-4053-4FFD-80C1-DAEBDDFF5DB4Q35542081-917D9C60-BB94-4FEE-98DD-D9CBB84FD2F7Q35566190-B9BCE3B9-D0A3-4CD7-99CF-B22E1C0FE6C2Q35977080-F035225B-2D53-49F5-B26A-708B5F169298Q36328971-AAAD5D56-7FE0-4CDB-BD8C-C975B84355C9Q36438953-61A25EFC-C1CE-457A-A121-6E52C8EBD6A7Q36456824-6DD6FEB0-2D02-4475-A1AF-6B8302920979Q36538707-85D1862C-0CB1-478A-985A-6B8DA4425C29Q36632851-5952F88E-ED0B-4FF0-B735-DF0E7E407D7AQ36735202-CC97D26B-70BB-4416-ACB8-D9D48BD83EB0Q36757810-E82299ED-AC39-4FF9-AAD9-C2A5FE0096B9Q36847287-19EC25AB-637B-468B-919A-85432F1AF426Q37268167-FE2A7A3F-1C96-4408-9A6A-2A82B7CA63CDQ37928639-49326187-DBD1-4D17-BD5A-8518A06A2A75Q37992997-5C138187-D4F7-453C-98ED-3D1E554033BEQ38062923-3D34A323-3AD3-48D0-AD35-0B46C55B620DQ38687487-1537CB39-B70F-4456-A5C8-C1C8A37CBF87Q38841252-5D4B9847-4833-413C-82F8-C69B3C6A28FDQ40588706-C1B18627-3A69-4008-A798-D5788199AC33Q41718743-E3D67464-10BA-4EAF-A54A-B384BF920952Q41723791-9BF0A0DE-3B95-45B8-9F47-B0CECDAFB250Q41734564-00105B3B-E8CC-4475-8739-BED244B1BEBAQ42537120-513FE615-5724-480B-8152-927BF835536AQ42557331-35BB2C8F-9E25-475A-A27F-BAFA0FB4B94CQ50543634-6303ECB9-44B3-4898-B799-6EFFC2866724Q51506580-F6F19661-A001-42E8-AF79-B80851DF0D38Q56889547-336D19AE-44D4-40A3-A57E-4367097F4D15
P2860
A prospective study of adverse reactions associated with vancomycin therapy.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
A prospective study of adverse reactions associated with vancomycin therapy.
@en
A prospective study of adverse reactions associated with vancomycin therapy.
@nl
type
label
A prospective study of adverse reactions associated with vancomycin therapy.
@en
A prospective study of adverse reactions associated with vancomycin therapy.
@nl
prefLabel
A prospective study of adverse reactions associated with vancomycin therapy.
@en
A prospective study of adverse reactions associated with vancomycin therapy.
@nl
P356
P1476
A prospective study of adverse reactions associated with vancomycin therapy.
@en
P2093
Collignon PJ
P304
P356
10.1093/JAC/16.2.235
P407
P577
1985-08-01T00:00:00Z